Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study (Q29775): Difference between revisions
Jump to navigation
Jump to search
Superraptor (talk | contribs) (Created a new Item) |
Superraptor (talk | contribs) (Added [en] label: Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study) |
||
| label / en | label / en | ||
Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study | |||
Revision as of 19:50, 7 November 2024
No description defined
- Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study |
No description defined |
|
Statements
The risk of venous thromboembolism (VTE) with gender-affirming hormone therapy (GAHT) in transgender and gender non-binary (TNB) youth is unclear. (English)
BACKGROUND (English)
© 2024 Wiley Periodicals LLC. (English)
2024
To identify the rate of VTE in a cohort of TNB youth followed in the transgender health clinic at Boston Children's Hospital, and to investigate the impact of congenital thrombophilia diagnosis on the use of GAHT. (English)
OBJECTIVE (English)
© 2024 Wiley Periodicals LLC. (English)
2024
ICD-9 and ICD-10 codes were used to identify eligible individuals, defined as (i) having a diagnosis of gender dysphoria and (ii) venous thromboembolism (VTE). (English)
METHODS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
Data were abstracted from a review of medical records. (English)
METHODS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
A second data query assessed TNB individuals who had an associated thrombophilia diagnosis. (English)
METHODS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
The primary analysis included 1860 individuals. (English)
RESULTS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
Total 942 individuals (50.6%) had started GAHT at the time of data analysis. (English)
RESULTS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
Mean age (±SD) at GAHT initiation was 16.8 (±1.9) years. (English)
RESULTS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
Five thrombotic events were identified in three (0.13%) individuals, all in the setting of additional VTE risk factors. (English)
RESULTS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
Only two of five thrombotic events occurred while receiving GAHT. (English)
RESULTS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
The rate of VTE in the GAHT cohort did not statistically differ from the rate of VTE in the non-GAHT cohort (0.1% vs. 0.2%, p = .62). (English)
RESULTS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
Of the 10 individuals diagnosed with a congenital thrombophilia, two transmasculine individuals received prophylactic anticoagulation prior to GAHT. (English)
RESULTS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
No VTE has been reported to date in this cohort. (English)
RESULTS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
In our cohort, VTE was rare in the TNB youth and was not associated with GAHT use. (English)
CONCLUSIONS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
TNB youth with congenital thrombophilia have not developed VTE in the setting of GAHT use to date. (English)
CONCLUSIONS (English)
© 2024 Wiley Periodicals LLC. (English)
2024
Charumathi (English)
Baskaran (English)
C
Stephanie A (English)
Roberts (English)
SA
Ellis (English)
Barrera (English)
E
Sarah (English)
Pilcher (English)
S
Riten (English)
Kumar (English)
R
9 October 2024
9 October 2024